RBC Capital Upgrades Regeneron Pharmaceuticals to Outperform, Announces $1076 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has upgraded Regeneron Pharmaceuticals (NASDAQ:REGN) from Sector Perform to Outperform and set a price target of $1076.
January 12, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals was upgraded by RBC Capital from Sector Perform to Outperform with a new price target of $1076.
Upgrades by analysts, especially from neutral to outperform ratings, can lead to increased investor confidence and a potential short-term rise in the stock's price. The new price target of $1076 suggests a significant upside from the current trading level, which may attract investors.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100